Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 9, 2008
A live webcast and replay of the Tuesday, September 16 session will be available
-
Sep 2, 2008
Company announced positive one-year results from the world's largest post-approval, prospective registry for a single drug-eluting stent (DES)
-
Sep 1, 2008
Overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI)
-
Aug 29, 2008
Boston Scientific obligation reduced from $250 to $19 million; Company to appeal remaining award
-
Aug 26, 2008
Company to present data from landmark SYNTAX clinical trial
-
Jul 21, 2008
"We were pleased with the quarter, especially with our expense management and working capital initiatives,” said CEO Jim Tobin.
-
Jul 2, 2008
Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms
-
Jun 26, 2008
A live webcast and replay of the July 22 conference call will be available
-
Jun 23, 2008
Legislation would help service veterans and the active armed forces better manage the challenges of chronic pain
-
Jun 19, 2008
Transactions further Company's plans to focus on core businesses and increase shareholder value